Login / Signup

Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis.

Mahdi AbastabarIman HaghaniTahereh ShokohiMohammad Taghi HedayatiSeyed Reza AghiliAli JediSulmaz DadashiShafigheh ShabanzadehTahereh HosseiniNarges AslaniJacques F MeisHamid Badali
Published in: Antimicrobial agents and chemotherapy (2018)
The in vitro activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to Candida species, Aspergillus species, and dermatophytes.
Keyphrases
  • candida albicans
  • genetic diversity
  • emergency department
  • pseudomonas aeruginosa
  • replacement therapy
  • cell wall
  • drug administration